University of Missouri-Kansas City School of Law

The urban public law school with a small liberal arts feel

Chris Holman Associate Professor of Law; J.D. (University of California, Berkeley Boalt School of Law); Ph.D. (University of California-Davis); B.S. (Cal-State-Hayward) email 816-235-2384 Vita Professor Chris Holman has been an associate professor at the University of Missouri-Kansas City School of Law since 2005. His primary research focus lies at the intersection of intellectual property and biotechnology, and he has taught classes in patent law; intellectual property; food, drug and biotechnology law, antitrust and competition law; drug and medical technology torts and property. Prior to becoming a law professor, Professor Holman served as vice-president of intellectual property and patent counsel at several Silicon Valley biotechnology companies, and worked as an associate at a major intellectual property law firm. He was also at one time a tenure-track chemistry professor in the California State University system. A native of California, Professor Holman received his Ph.D. in biochemistry and molecular biology from the University of California at Davis, and engaged in post-doctoral drug discovery research at Roche Biosciences in Palo Alto, California. He then attended law school at UC Berkeley’s Boalt Hall, during which time he was an associate editor for the Berkeley Technology Law Journal and served as a full-time judicial extern in federal court in the Northern District of California. As a molecular biologist, Professor Holman published a number of articles in the area of protein engineering and the relationship between enzyme structure and function. Some of his more recent legal articles include “Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents,” Berkeley Tech. L. J. (forthcoming 2009); “Trend in Human Gene Patent Litigation,” Science, 322:198-99 (2008); “The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation,” 76 UMKC L. Rev. 295 (2007); “Patent Border Wars: Defining the Boundary Between Scientific Discoveries and Patentable Inventions,” Trends in Biotechnology, 25: 539-43 (2007); “Is Lilly Written Description a Paper Tiger?: A Comprehensive Assessment of the Impact of Eli Lilly and Its Progeny in the Courts and PTO,” 17 Alb. L.J. Sci. & Tech. 1 (2007); “Do Reverse Payment Settlements Violate The Antitrust Laws?,” 23 Santa Clara Computer & High Tech. L.J. 489 (2007); “Biotechnology’s Prescription for Patent Reform,” 5 J. Marshall Rev. Intell. Prop. L. 318 (2006); and “Clearing a Path through the Patent Thicket,” Cell, 125: 629-633 (2006). You can access my papers on the Social Science Research Network (SSRN) at: http://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=537838